The Cryptonomist

تقوم إيثينا بتوسيع الأنابيب التي تغذي دولارها الصناعي، وهذه المرة تمر المواسير عبر أسواق الائتمان على طراز وول ستريت بدلًا من مشتقات العملات المشفرة. فقد عقد مُصدر العملة المستقرة شراكة مع وسيط أولي للرقمية من الأصول فالكون إكس لإطلاق منشأة تخزين مؤمّنة بقيمة 1 مليار دولار لـ USDe، وهي بنية مصممة لدفع الأصول التي تدعم USDe إلى قروض مؤسسية مفرطة الضمان بدلًا من تركها مكشوفة حصريًا لتقلبات معدلات تمويل العقود الآجلة الدائمة.
الملخص
قامت إيثينا وفالكون إكس بإعداد منشأة تخزين مؤمّنة بقيمة 1 مليار دولار لنشر أصول مدعومة بـ USDe في قروض مؤسسية مفرطة الضمان.

Moderna, Inc. stock shows a bullish daily structure, yet shorter-term charts flash caution. The gap between the broader trend and the intraday tape defines the core story for MRNA right now. It sets up a classic trend-versus-pullback debate.
MRNA — daily chart with candlesticks, EMA20/EMA50 and volume.
Key takeaways
MRNA closed at $62.96 on August 18, holding above all three key daily EMAs in a textbook bullish stack.
Daily RSI14 at 55.04 and a positive MACD histogram of 0.92 confirm intact uptrend momentum with no overbought signal.
Hourly momentum is cooling: RSI14 slipped to 46.62 and MACD turned negative, though the daily trend remains firmly intact.
Moderna and Merck’s Phase 3 melanoma trial met both recurrence-free and distant metastasis-free survival endpoints.
MRNA shares climbed 44.2% in the prior six months, with elevated volatility (ATR14 of 3.76) still a defining feature.
Daily Chart: EMA Stack Confirms Bullish Structure
The daily chart maintains a clear bullish posture for Moderna, Inc. stock. Price holds above all three key moving averages, and constructive momentum readings support further upside.
EMA Structure and Trend Confirmation
MRNA closed at $62.96 on August 18, slightly below the $63.04 open, after tagging a high of $64.37 and a low of $62.13. Volume came in at just over 4 million shares. The candle itself reads as a mild pause rather than a reversal.
The moving average structure remains clearly constructive. The 20-day EMA sits at $60.74, the 50-day EMA at $59.54, and the 200-day EMA far below at $49.29. That stacking is a textbook signature of an established uptrend. Price holds above all three EMAs, with the long-term average well beneath the shorter ones.
Momentum and Volatility Signals
The daily RSI14 reads 55.04, comfortably in neutral-to-bullish territory without any hint of overbought exhaustion. The MACD line at 0.59 sits above its signal line at -0.33, producing a positive histogram of 0.92. That is healthy bullish momentum, not a stretched reading. There is still room to run before this indicator flags fatigue.
The Bollinger Bands add context on volatility. The mid-band sits at $58.38, with the upper band at $65.39 and the lower band at $51.37. Price is trading in the upper half of that envelope—consistent with an uptrend not yet at extremes. Meanwhile, the ATR14 of 3.76 confirms daily ranges remain wide. This is a reminder that volatility in MRNA stays elevated compared to a quiet consolidation phase.
The daily pivot sits at $63.15, with resistance at $64.18 (R1) and support at $61.94 (S1). Overall, the system’s regime tag on this timeframe reads bullish, and the indicator mix agrees with that label.
1H Timeframe: Confirmation Fades as Momentum Cools
The hourly chart no longer confirms the daily bullish push. Short-term momentum has softened for Moderna, Inc. stock, with price slipping below near-term averages and the regime shifting to neutral.
Price closed at $62.95, down from a $63.77 open, after touching a high of $64.01 and a low of $62.75. Notably, the 20-hour EMA at $63.64 now sits above price, while the 50-hour EMA at $62.35 holds close behind. That is a subtle but real shift: short-term price action has slipped beneath its own near-term average.
Momentum on this timeframe is softening too. The hourly RSI14 has dropped to 46.62, just under the neutral 50 line. The MACD line at 0.25 has crossed below its signal at 0.51, producing a negative histogram of -0.26. In other words, the intraday momentum that carried MRNA higher over recent sessions is now losing steam. However, this does not automatically invalidate the daily bias. It simply suggests the market is digesting the recent advance rather than reversing outright.
The hourly Bollinger setup shows price trading closer to the lower half of its band. The mid-line sits at $63.87 and the lower band at $62.23. The pivot at $63.24, alongside resistance at $63.73 and support at $62.46, frames a fairly tight intraday range. The regime here is labeled neutral—the clearest signal that the 1H timeframe is not matching the daily bullish conviction. This is the conflict worth flagging: daily trend intact, hourly momentum stalling.
15-Minute View: Execution Context Only
The 15-minute chart offers short-term execution context rather than shaping the broader thesis for Moderna, Inc. stock. The tape leans mildly bearish, though this window is purely useful for timing entries.
Price closed at $62.95, below both the 20-period EMA at $63.57 and the 50-period EMA at $63.71. Still, it holds above the 200-period EMA at $62.10. The 15m RSI14 at 38.49 points to short-term selling pressure. At the same time, the MACD histogram is essentially flat at -0.01, reflecting indecision rather than strong directional conviction.
Price is also hugging the lower Bollinger band, with the mid-line at $63.49 and the lower band at $62.71. The nearby pivot at $63.09, support at $62.61, and resistance at $63.43 will likely define the next few hours of trading. Therefore, short-term traders should treat this zone as the immediate battleground rather than a signal of trend change.
News Flow Adds a Fresh Bullish Catalyst
The fundamental backdrop for Moderna, Inc. stock has turned notably positive. A major clinical milestone now reinforces the existing uptrend.
Moderna and Merck announced that their Phase 3 INTerpath-001 trial of intismeran autogene plus KEYTRUDA® met its endpoints. The trial achieved recurrence-free survival and distant metastasis-free survival in patients with completely resected Stage IIB-IV melanoma. Bloomberg reported that shares of both companies soared after the personalized cancer vaccine helped cut melanoma recurrence. The report called it an important milestone for the embattled mRNA-based technology.
Meanwhile, a Yahoo Finance piece noted that MRNA shares had already climbed 44.2% over the prior six months, hitting $63.36. That move came partly on the back of solid quarterly results. Together, these two developments—a strong pre-existing move plus a fresh clinical catalyst—explain why the daily trend has stayed intact. The intraday charts, in turn, are simply pausing for breath.
Bullish Scenario
The bullish case for Moderna, Inc. stock rests on the daily trend reasserting itself. A reclaim of the hourly EMA20 near $63.64, followed by a push through the daily pivot at $63.15, would be the first sign. Clearing R1 resistance at $64.18 would then confirm the pullback was shallow.
Given the strong EMA200 support far below at $49.29 and a still-positive daily MACD histogram, the structural backdrop favors continuation if buyers step back in. The melanoma trial news provides exactly the kind of fundamental tailwind that could fuel such a move. Follow-through volume will be the confirming signal to watch.
Bearish Scenario
The bearish risk centers on short-term weakness spreading rather than resolving. A break below the daily S1 support at $61.94, combined with the 15m chart losing its lower Bollinger band near $62.71, would suggest the pullback is deepening.
In that case, a retest of the daily EMA20 at $60.74 or even the EMA50 at $59.54 becomes plausible. What would invalidate the bullish thesis most clearly is a dual-timeframe breakdown. If the hourly regime shifts from neutral to outright bearish, with RSI14 sliding well below 40 across both the 1H and 15m timeframes, the daily uptrend would face its first real test.
Closing Take
Overall, Moderna, Inc. stock remains in a bullish daily posture, backed by a clean EMA stack, positive MACD momentum, and a fresh clinical catalyst from the Merck-partnered melanoma trial. In contrast, the hourly and 15-minute timeframes show that short-term momentum has cooled. Price has slipped under near-term averages, and RSI readings are drifting toward oversold on the lowest timeframe.
Elevated ATR readings on the daily chart confirm that volatility remains a feature, not a bug, of this name. Positioning around current levels should account for that two-speed dynamic. Traders will want to watch how price behaves around the daily pivot and S1/R1 levels before drawing firm conclusions about the next leg.
FAQ
What is the current trend for Moderna, Inc. stock?
The daily chart shows a clear bullish trend. MRNA trades above its 20-day EMA ($60.74), 50-day EMA ($59.54), and 200-day EMA ($49.29). The daily RSI14 at 55.04 and positive MACD histogram of 0.92 confirm constructive momentum without overbought signals.
Why is the hourly chart showing weakness?
The hourly chart reflects short-term digestion. The RSI14 has slipped to 46.62 and the MACD turned negative. However, this cooling does not invalidate the daily uptrend—it suggests the market is absorbing the recent advance rather than reversing.
What news is driving Moderna, Inc. stock?
Moderna and Merck announced positive Phase 3 INTerpath-001 trial results for their personalized cancer vaccine in melanoma. The trial met recurrence-free and distant metastasis-free survival endpoints. Additionally, MRNA shares had already gained 44.2% in the prior six months.
What are the key levels to watch for MRNA?
The daily pivot sits at $63.15, with resistance at $64.18 (R1) and support at $61.94 (S1). A reclaim of the hourly EMA20 near $63.64 would favor bulls. A break below S1 at $61.94 would suggest the pullback is deepening toward the daily EMA20 at $60.74.
Disclaimer: This article is for informational purposes only and does not constitute financial advice, an investment recommendation, or a solicitation to buy or sell any financial instrument or cryptocurrency. The analysis provided is not indicative of future results. Investing in crypto assets and financial markets carries a high risk of capital loss. Always do your own research (DYOR) and consult a qualified financial advisor before making any decision.
Article produced with the assistance of artificial intelligence and reviewed by the editorial team.

Merck & Company, Inc. stock shows a clear split between timeframes. The daily chart remains firmly bullish, while shorter timeframes reveal cooling momentum. Fresh clinical news from the Merck-Moderna melanoma vaccine program adds another layer. Trend and timing must now be read separately.
MRK — daily chart with candlesticks, EMA20/EMA50 and volume.
Key takeaways
Merck & Company, Inc. stock closed at 135.17, with the daily EMA20/EMA50/EMA200 stack in classic bullish alignment.
Daily RSI14 at 65.81 and a positive MACD histogram of 0.44 confirm momentum is still expanding to the upside.
Hourly RSI14 has cooled to 50.99 and the 1H MACD histogram turned negative (-0.27), signaling short-term hesitation.
The Phase 3 INTerpath-001 melanoma vaccine trial met its primary endpoints, driving shares in both Merck and Moderna higher.
Price is boxed in a tight range near the daily pivot at 136.01, with S1 at 134.04 and R1 at 137.14.
Daily Trend: Bulls Still in Control of Merck Stock
The daily trend for Merck & Company, Inc. stock remains firmly bullish. The EMA20 at 131.06, EMA50 at 126.90, and EMA200 at 114.28 are stacked in classic uptrend order. This alignment signals a market where dips continue to attract buyers on a multi-month view.
Notably, Merck closed at 135.17 after printing a session high of 137.98 and a low of 134.88. The close came in below the open of 137.24, indicating sellers pushed back near the highs. Even so, the broader structure stayed intact. The stock has also been cited jumping to 52-week highs on strong earnings momentum, reinforcing the established advance.
Short-Term Momentum Diverges from the Daily Uptrend
Shorter timeframes tell a more cautious story for Merck & Company, Inc. stock. While the daily trend points higher, intraday momentum has clearly cooled. This divergence leaves the stock in a holding pattern that demands patience from bulls.
Hourly Indicators Point to Cooling
Meanwhile, the 1H RSI14 has dropped to 50.99, settling in neutral territory. The 1H MACD line sits at 0.50 against a signal of 0.77, producing a negative histogram of -0.27. In short, short-term momentum has turned lower even as the daily trend stays intact. This is a case where timeframes disagree: the bigger trend is bullish, but the immediate momentum is fading.
15-Minute Chart Shows Intraday Weakness
On the 15-minute chart, RSI14 reads 39.99 — the weakest reading across all three timeframes. The MACD histogram is barely positive at 0.01, with the line at -0.18 versus a signal of -0.20. However, the near-flat reading suggests the decline may be losing steam. No clean reversal signal has emerged yet.
Volatility and Pivots Frame the Near-Term Picture
Merck & Company, Inc. stock is consolidating in a tighter range after a wide daily move. The volatility structure and pivot levels together define where the next directional break could occur.
Daily Bollinger Bands show price at 135.17, above the mid-band of 130.99 and close to the upper band at 136.39. Daily ATR14 stands at 3.25, confirming wide swings on this timeframe. In contrast, the hourly bands are far tighter, with a mid-band at 135.71 and an ATR14 of just 1.00. The 15-minute ATR14 is even narrower at 0.29. The stock made a large daily move and is now consolidating in lower volatility.
On the pivot side, the daily level sits at 136.01, with resistance R1 at 137.14 and support S1 at 134.04. Price closed below the daily pivot — a mildly cautious signal inside a bullish broader trend. Meanwhile, the hourly pivot is 135.29, with R1 at 135.48 and S1 at 134.98. The 15-minute structure mirrors this. Price is boxed inside this narrow band, which explains the indecisive short-term tone.
Melanoma Vaccine Trial Provides a Fresh Catalyst
A meaningful clinical update is now in play alongside the technical picture for Merck & Company, Inc. stock. Merck and Moderna announced that the Phase 3 INTerpath-001 trial met its primary endpoints. The combination of intismeran autogene plus KEYTRUDA showed significant improvement in recurrence-free survival and distant metastasis-free survival. The trial evaluated patients with resected Stage IIB-IV melanoma.
Notably, reports from CNBC and Bloomberg confirmed the regimen extended the time patients lived without their melanoma returning. The improvement was measured against KEYTRUDA alone. Shares in both companies surged on the news. Therefore, this pipeline catalyst can shift sentiment beyond what the daily candle alone reflects. After all, the news broke after the last completed daily bar. The fundamental backdrop was already constructive, with Merck highlighted among names hitting 52-week highs on strong earnings momentum.
Bullish Scenario for Merck Stock
The bullish case for Merck & Company, Inc. stock rests on the daily trend reasserting control. First, a reclaim of the daily pivot at 136.01, followed by a push through R1 at 137.14, would put the recent high of 137.98 back in focus. Hourly RSI would need to move above 50 with conviction for this to carry weight. The hourly MACD histogram would also need to flip positive again.
At the same time, a daily RSI holding in the mid-60s without rolling over would support the broader uptrend. The EMA20/EMA50/EMA200 stack must stay intact. Sustained strength tied to the melanoma trial results and ongoing earnings momentum would be a logical trigger for such a move.
Bearish Risks and Invalidation Points
Bearish risk centers on a loss of daily structure. Specifically, a break below S1 at 134.04 would be the first warning sign. A deeper slide toward the daily EMA20 at 131.06 would signal that recent strength is fading rather than pausing.
In contrast, if the daily RSI drops decisively below 60 while the MACD histogram shrinks from its current 0.44, that would confirm momentum is genuinely turning. On the hourly chart, a break below the EMA50 at 133.87 would add weight to this bearish path. Such a combination would invalidate the near-term bullish setup. The longer-term EMA200 trend at 114.28 would still remain technically bullish, but the tactical picture would shift.
Positioning and Outlook for Merck Stock
Overall, Merck & Company, Inc. stock presents a split picture. The daily trend is bullish, supported by well-aligned EMAs, a positive MACD, and RSI still under overbought extremes. However, the hourly and 15-minute timeframes show cooling momentum and a tight, undecided range around the 135 area.
Still, given the ATR readings across timeframes, volatility could pick up quickly. The fresh clinical catalyst from the melanoma vaccine trial adds urgency. Therefore, near-term direction hinges on how price behaves around the daily pivot at 136.01 and the S1/R1 hourly band. Until smaller-timeframe momentum realigns with the daily trend, the setup remains one of controlled uncertainty rather than a clean directional signal.
FAQ
Is Merck & Company, Inc. stock still in a daily uptrend?
Yes. The daily EMA20 at 131.06, EMA50 at 126.90, and EMA200 at 114.28 are stacked in classic bullish order. Daily RSI14 at 65.81 and a positive MACD histogram of 0.44 confirm momentum is still expanding to the upside. The stock has also been cited reaching 52-week highs on strong earnings momentum.
Why is intraday momentum cooling for Merck stock?
Hourly RSI14 has cooled to 50.99, which is neutral territory. The 1H MACD histogram has turned negative at -0.27. On the 15-minute chart, RSI14 is at 39.99 — the weakest reading across all timeframes — indicating short-term sellers remain active even as the daily trend stays intact.
What is the Merck-Moderna melanoma vaccine news?
Merck and Moderna announced that the Phase 3 INTerpath-001 trial met its primary endpoints. The combination of intismeran autogene plus KEYTRUDA significantly extended recurrence-free survival and distant metastasis-free survival in patients with resected Stage IIB-IV melanoma, compared with KEYTRUDA alone.
What are the key levels to watch for Merck stock?
The daily pivot at 136.01 is the near-term battleground. Resistance sits at R1 137.14, with the recent high at 137.98. Support lies at S1 134.04, with the daily EMA20 at 131.06 serving as a deeper floor. On the hourly chart, the EMA50 at 133.87 is also a critical level to monitor.
Disclaimer: This article is for informational purposes only and does not constitute financial advice, an investment recommendation, or a solicitation to buy or sell any financial instrument or cryptocurrency. The analysis provided is not indicative of future results. Investing in crypto assets and financial markets carries a high risk of capital loss. Always do your own research (DYOR) and consult a qualified financial advisor before making any decision.
Article produced with the assistance of artificial intelligence and reviewed by the editorial team.

Analog Devices, Inc. stock is caught between two competing stories. The daily chart still shows an intact uptrend. The hourly chart, however, shows momentum fading. That tension matters for traders positioning around this week’s earnings reaction.
ADI — daily chart with candlesticks, EMA20/EMA50 and volume.
Key takeaways
ADI closed at $376.63, down from an intraday high of $385.90 and below the $390.17 level flagged in recent coverage.
The daily chart remains above the EMA200 at $347.52, even though price sits below the EMA20 at $381.44 and the EMA50 at $384.91.
The hourly chart shows a bearish regime, with RSI14 at 41.49 and a negative MACD histogram of -1.57.
Daily RSI14 reads 46.7 and the MACD histogram has turned positive at 1.86, hinting at possible stabilization.
Analysts project quarterly earnings of $3.33 per share on revenue of $3.92 billion ahead of this week’s reaction.
Daily Timeframe: Neutral Regime, but the Long-Term Trend Is Intact
The daily chart still supports an intact long-term trend, even though short-term momentum has cooled. Analog Devices, Inc. stock closed the latest session at $376.63, down from an intraday high of $385.90. That close sits well off the $390.17 level flagged in recent coverage. ADI’s six-month run had beaten the S&P 500 by 8.9%. In other words, this is a pullback inside a strong prior advance, not yet a trend reversal.
The daily regime reading is neutral. Price sits below the EMA20 at $381.44 and the EMA50 at $384.91. That shows short-term momentum has cooled. However, the EMA200 sits far below at $347.52. The stock remains firmly above its long-term trend average. That gap is significant. It tells us the primary uptrend has not been broken, even though the last few sessions have been rough.
RSI14 on the daily chart reads 46.7. That is a neutral number, neither overbought nor oversold. It fits a stock digesting gains rather than collapsing. MACD offers a more constructive detail. Its line sits at -0.51 versus a signal at -2.37. The histogram has turned positive at 1.86. That combination usually signals momentum is stabilizing after a down leg, even though the MACD line itself remains negative. It is an early, tentative sign of the daily trend regaining its footing.
Bollinger Bands show price essentially parked at the mid-band at $377.11. The upper band sits at $396.94 and the lower band at $357.28. There is no extreme positioning in either direction. Meanwhile, the ATR14 of 12.77 confirms real volatility, consistent with a session range of nearly $16. The daily pivot point sits at $377.60, with resistance at $384.93 (R1) and support at $369.30 (S1). Price closing just under the pivot keeps the near-term bias cautious, even as the broader picture stays constructive.
Hourly Chart Confirms Near-Term Weakness
Short-term selling pressure is building on the hourly chart, even as the daily trend holds. The H1 regime is flagged bearish, and its indicators agree. Price at $376.96 trades below the H1 EMA20 at $381.05, the EMA50 at $382.75, and the EMA200 at $383.92. That is a fully bearish stacking order for the short-term trend. RSI14 at 41.49 confirms weak momentum, sitting below the midline.
MACD on the hourly timeframe is more decisively negative than on the daily. Its line sits at -3.32, well below the signal at -1.76. The histogram is negative at -1.57. That means downside momentum has been accelerating into the close, not fading. Therefore, while the daily chart hints at stabilization, the hourly chart tells a more urgent story. Sellers have been in control through the most recent hours of trading.
This is a textbook conflict between timeframes. The daily structure argues for a pullback within an uptrend. The hourly structure argues for active, intensifying short-term selling pressure. Both can be true at once. A healthy uptrend can absorb sharp intraday corrections. Still, near-term risk is elevated, particularly heading into an earnings reaction that can move the stock quickly in either direction.
15-Minute Chart: A Tentative Bounce Attempt
On the 15-minute chart, the picture softens slightly. RSI14 has climbed to 54.84. The MACD histogram has turned positive at 1.12, with its line at -1.94 above the signal at -3.06. Price at $376.96 is trading above the 15m EMA20 at $374.56. It remains below the EMA50 at $379.11 and the EMA200 at $382.38.
In practical terms, this looks like a short-term bounce attempt inside a still-lower short-term structure. It is useful only as execution context, not as a signal that changes the broader bias. The relevant levels are the pivot at $375.69, resistance at $378.37, and support at $374.28.
Bullish Scenario for Analog Devices, Inc. Stock
The bullish case for Analog Devices, Inc. stock depends on the daily chart reasserting control above its short-term averages. If ADI reclaims the daily pivot at $377.60 and pushes back above the EMA20 at $381.44, the improving MACD histogram would gain credibility. That would support an early reversal signal rather than a temporary pause. A close back above the daily EMA50 at $384.91 and through R1 at $384.93 would be a stronger confirmation that the pullback is over.
Fundamentally, the setup for a bullish resolution has some support in the news flow. Coverage ahead of earnings pointed to analysts projecting quarterly earnings of $3.33 per share and revenue of $3.92 billion. That implies substantial year-over-year growth, alongside particular strength expected in key end markets. Separate commentary noted ADI’s industrial and data center growth, AI exposure, and strong margins. Those factors have been used to justify its premium valuation. If those growth themes are confirmed, the daily uptrend would have the fundamental backing to resume. That uptrend is still intact above the EMA200.
Bearish Scenario and What Would Invalidate the Bullish Case
The bearish case is built on the hourly weakness spreading into the daily chart and breaking key support. A break below the daily pivot support at $369.30 would put the lower Bollinger band at $357.28 into play. A deeper slide would begin testing the EMA200 near $347.52. That level currently defines the entire bull case. Notably, some recent coverage has explicitly questioned ADI’s premium valuation. It highlighted reasons for caution after a stock that had already climbed 20% and outpaced the S&P 500 by 8.9%. That kind of run tends to leave less room for disappointment.
If the hourly bearish regime persists after the earnings reaction, the daily chart’s tentative MACD stabilization would likely fail to develop into a genuine reversal. That condition means price stays capped below the H1 EMA20, EMA50, and EMA200. In that case, the neutral daily regime would tilt toward a more sustained corrective phase rather than a simple pullback.
Closing Take
Overall, Analog Devices, Inc. stock sits at a genuine inflection point between an intact daily uptrend and fading hourly momentum. The daily trend remains technically intact thanks to the wide cushion above the EMA200. The hourly chart, however, shows real and accelerating short-term selling pressure heading into the earnings reaction. That combination argues for caution rather than conviction in either direction.
At the same time, ATR readings confirm elevated volatility across timeframes. An earnings-driven catalyst is also on the calendar. The coming sessions should clarify whether this is a routine pullback or the start of something more significant. Until the daily pivot and EMA20 are reclaimed — or decisively lost — the fair read is one of uncertainty, not a clean directional bet.
FAQ
Is the long-term uptrend in ADI still intact?
The daily chart remains above the EMA200 at $347.52. That wide cushion keeps the primary uptrend intact, even though price closed at $376.63 below the EMA20 and EMA50.
What would confirm that the pullback is over?
A close back above the daily EMA50 at $384.91 and through R1 at $384.93 would strengthen the bullish case. First, however, ADI needs to reclaim the daily pivot at $377.60 and the EMA20 at $381.44.
What would invalidate the bullish case?
A break below the daily pivot support at $369.30 would put the lower Bollinger band at $357.28 into play. A deeper slide toward the EMA200 near $347.52 would begin testing the level that defines the bull case.
What are the earnings expectations for Analog Devices?
Coverage ahead of earnings pointed to analyst projections of $3.33 per share and revenue of $3.92 billion, implying substantial year-over-year growth and strength in key end markets.
Disclaimer: This article is for informational purposes only and does not constitute financial advice, an investment recommendation, or a solicitation to buy or sell any financial instrument or cryptocurrency. The analysis provided is not indicative of future results. Investing in crypto assets and financial markets carries a high risk of capital loss. Always do your own research (DYOR) and consult a qualified financial advisor before making any decision.
Article produced with the assistance of artificial intelligence and reviewed by the editorial team.

Target Corporation stock holds a daily uptrend, supported by an earnings beat and a raised full-year outlook. However, the 1-hour chart shows hesitation where the market must choose its next direction. The daily structure favors bulls, but the shorter-term picture demands caution.
TGT — daily chart with candlesticks, EMA20/EMA50 and volume.
Key takeaways
TGT closed at 152.48 on the daily chart, above EMA20 (147.84), EMA50 (140.50), and EMA200 (122.69), confirming a bullish daily structure.
The hourly RSI14 at 47.25 and negative MACD histogram signal short-term neutrality, creating a timeframe conflict with the daily uptrend.
Target beat Q2 earnings expectations and raised its full-year guidance, lending fundamental support to the technical uptrend.
Daily RSI14 at 63.9 leaves room for continuation before reaching overbought levels, while the daily pivot at 152.80 marks the immediate decision zone.
Daily Trend: The Core Bullish Structure for Target Corporation Stock
Target Corporation stock remains in a firmly bullish daily uptrend, trading well above all major moving averages and confirming a textbook bullish alignment.
On the daily timeframe, TGT closed at 152.48 after printing a high of 154.26 and a low of 151.66. Volume reached roughly 4.78 million shares. The stock sits firmly above its EMA20 at 147.84, EMA50 at 140.50, and EMA200 at 122.69. This stacked moving average alignment is a textbook sign of a healthy, well-established uptrend. It also confirms the platform’s daily regime reading of “bullish.”
Meanwhile, the daily RSI14 sits at 63.9, which is elevated but not yet in overbought territory. Buyers remain in control, though momentum has room before it becomes stretched. The daily MACD line at 4.56 stays above its signal line at 4.48, with a histogram of just 0.08. That thin histogram reading is worth noting: bullish momentum is intact but losing some of its earlier acceleration.
Volatility and Pivot Levels
Beyond momentum, Bollinger Bands on the daily chart show the mid-band at 147.12. The upper band stands at 158.95 and the lower band at 135.28. Price at 152.48 sits comfortably between the mid and upper bands. This leaves technical room to extend higher before volatility bands flag an overextended move. The daily ATR14 of 3.62 confirms that Target Corporation stock trades with meaningful but not extreme daily swings.
Additionally, pivot levels add useful short-term context. The daily pivot point stands at 152.80, with resistance at 153.94 for R1 and support at 151.34 for S1. The latest daily close of 152.48 sits just below the pivot. The stock is therefore hovering at a decision zone rather than in a clear breakout posture.
1-Hour Timeframe: Confirmation Turns Into Complication
The 1-hour chart does not confirm the daily bullish trend. Instead, it shows neutral-to-bearish signals that create a clear timeframe conflict with the daily structure.
On the hourly chart, TGT closed at 152.54. It sits slightly below its EMA20 at 153.01 but still above its EMA50 at 152.36. It also remains well above its EMA200 at 145.63. In contrast to the daily trend, the platform tags this hourly regime as “neutral.” The indicators back that assessment.
At the same time, the hourly RSI14 reads 47.25, leaning mildly toward sellers. The hourly MACD line at -0.19 sits below its signal line at -0.12. The histogram registers -0.07. This is a clear short-term bearish tilt. It directly complicates the otherwise clean daily bullish narrative. Therefore, while the bigger trend points higher, the immediate hourly momentum does not yet confirm a fresh push upward.
Bollinger Band and Pivot Signals
On the volatility front, hourly Bollinger Bands show the mid-band at 153.20. The upper band stands at 155.57 and the lower band at 150.84. Price closing below the mid-band reinforces the sense of a short-term pause rather than continuation. The hourly ATR14 of 1.46 indicates that intraday volatility has cooled compared to the daily range. This is consistent with a market digesting recent news rather than trending aggressively.
Hourly pivots place the pivot point at 152.70. Resistance sits at 153.70 for R1 and support at 151.54 for S1. With the close at 152.54, price sits almost exactly on the pivot. This is a classic sign of short-term indecision.
15-Minute Execution Context
The 15-minute chart shows a compressed, indecisive market with tentative signs of short-term stabilization.
Price closed at 152.54, below the EMA20 at 152.90 and EMA50 at 153.04. However, it remains above the EMA200 at 152.59. This tight clustering of moving averages reflects a market compressing after the earnings-driven move. It is not yet committing to a new direction.
Notably, the 15-minute RSI14 sits at 46.18, also neutral. The 15-minute MACD line at 0.07 sits above its signal line at 0.02. This produces a small positive histogram of 0.05. The reading marks a subtle divergence from the hourly bearish tilt. It suggests a possible short-term stabilization attempt.
The 15-minute pivot point stands at 152.45, with resistance at 153.19 for R1 and support at 151.79 for S1. Price closing just above the pivot hints at buyers defending this zone for now. However, the signal remains tentative given the very short timeframe.
The News Backdrop: Why Target Corporation Stock Is in Focus
Target Corporation stock moved on an earnings beat, raised full-year guidance, and a notable tariff refund that boosted the company’s bottom line.
The technical picture cannot be separated from the news flow driving this session. Target reported second-quarter results that beat expectations. The CEO was described as “encouraged” by the company’s turnaround traction. According to Bloomberg, the retailer lifted its full-year guidance after results outpaced estimates. This suggests the company may be moving past a lengthy sales slump.
This combination of a raised outlook, sales recovery signals, and margin support from the tariff refund gives fundamental weight to the daily uptrend. CNBC reported that Target hiked its outlook as sales rebounded. Ahead of the report, analysts had expected quarterly earnings of $2.30 per share, up from $2.05 per share in the year-ago period, according to Yahoo Finance. The technical strength on the daily chart is backed by tangible operational improvement.
Bullish Scenario
The bullish case for Target Corporation stock rests on the daily structure holding its ground. If price reclaims the daily pivot at 152.80 and pushes through R1 at 153.94, that opens the path toward the upper Bollinger Band near 158.95.
A recovery of the hourly EMA20 at 153.01, combined with the hourly MACD turning positive again, would resolve the current hourly hesitation in favor of the bulls. Given the daily RSI at 63.9 and the EMA stack still fully bullish, there is technical room for continuation. The positive earnings narrative could continue to support buying interest.
Bearish Scenario
On the other hand, the bearish argument centers on the hourly weakness spreading into the daily chart. A break below the daily S1 at 151.34, especially with the hourly MACD histogram deepening further into negative territory, would suggest the short-term pause is turning into an actual pullback.
Should price also lose the 15-minute EMA200 near 152.59 decisively, that would remove one of the few short-term supports still favoring buyers. In this scenario, a retest of the daily EMA20 near 147.84 would become a realistic downside target. That would still leave the broader uptrend technically intact but clearly under pressure.
Closing Take
Overall, Target Corporation stock remains in a daily uptrend that is fundamentally supported by an earnings beat and a raised full-year outlook. However, the hourly chart sends a more cautious signal. Negative MACD momentum and a neutral regime reading conflict with the daily bullish picture.
Meanwhile, the 15-minute chart shows tentative signs of short-term stabilization, but nothing conclusive. Given the daily ATR14 of 3.62 and the current standoff at the hourly pivot, volatility is likely to stay elevated in the near term. Positioning around these levels should account for this timeframe conflict rather than assuming automatic continuation. The next few sessions should clarify whether the daily trend reasserts itself or the hourly hesitation deepens into a broader consolidation.
FAQ
Is Target Corporation stock still in an uptrend?
Yes. The daily chart shows TGT trading well above its EMA20 (147.84), EMA50 (140.50), and EMA200 (122.69). The platform’s daily regime reading remains “bullish,” confirming a healthy uptrend structure with stacked moving averages.
What is causing the short-term hesitation in Target Corporation stock?
The hourly chart shows neutral-to-bearish signals, with RSI14 at 47.25 and a negative MACD histogram. Price sits near the hourly pivot at 152.70, a classic sign of indecision following the volatile reaction to the earnings report.
What are the key levels to watch for Target Corporation stock?
On the upside, watch the daily R1 at 153.94 and the upper Bollinger Band near 158.95. On the downside, key support sits at the daily S1 of 151.34, followed by the daily EMA20 at 147.84.
What fundamental factors are supporting Target Corporation stock?
Target beat Q2 earnings expectations and raised its full-year guidance. A tariff refund also boosted the bottom line. Analysts had expected earnings of $2.30 per share, up from $2.05 a year ago, signaling improving operational momentum.
Disclaimer: This article is for informational purposes only and does not constitute financial advice, an investment recommendation, or a solicitation to buy or sell any financial instrument or cryptocurrency. The analysis provided is not indicative of future results. Investing in crypto assets and financial markets carries a high risk of capital loss. Always do your own research (DYOR) and consult a qualified financial advisor before making any decision.
Article produced with the assistance of artificial intelligence and reviewed by the editorial team.

اعتبارًا من 19 أغسطس 2026، تستقر ETH/USDT عند 1934.45، وتتذبذب فوق المتوسطات اليومية (EMAs) الخاصة بها، بينما لا يزال المزاج العام حذرًا. يجد سوق العملات المشفرة لإيثريوم نفسه عند مفترق طرق؛ إذ يتصادم الزخم قصير الأجل مع التردد طويل الأجل، ما يخلق خلفية متوترة للمتداولين.
ETH/USDT — مخطط يومي مع الشموع ومؤشرات EMA20/EMA50 والحجم.
أهم النقاط
تتداول ETH عند 1934.45، أعلى من EMA20 (1893.48) وEMA50 (1872.94)، لكن دون EMA200 (2140.04).
RSI اليومي عند 60.14 يشير إلى ظروف صعودية دون الاقتراب من تشبع الشراء المرهق.

اعتبارًا من 19 أغسطس 2026، تقع عملة بيبي بين ميل يومي هابط وبين ارتداد قصير الأجل ينعكس بهدوء في ارتفاع الزخم. ما زال الرسم البياني اليومي يميل لصالح البائعين، بينما تُظهر الأطر الزمنية الأصغر اهتمامًا بالشراء. إن قراءة كل إطار زمني قبل مطاردة أي من الطرفين المتطرفين أمر مهم، لأن الإشارات المتضاربة غالبًا ما تُوقع المتداولين غير الصبورين في الفخ.
زوج PEPE/USDT — الرسم البياني اليومي مع الشموع، ومتوسطات EMA20/EMA50 والحجم.
أبرز النقاط
بلغت سيطرة بيتكوين 56.5% من إجمالي القيمة السوقية للعملات المشفرة التي تتجاوز 2.29 تريليون دولار، وفقًا لـ CoinGecko.

عند 9.80 دولارات في 19 أغسطس 2026، تقع عملة Chainlink الرقمية بدقة على الحد العلوي لبولينجر اليومي، وهو إعداد متوتر يتطلب خيارًا واضحًا. هل هذا اختراق حقيقي، أم أن LINK تسخن بشكل زائد؟ إن مؤشر RSI اليومي عند 74.29 يصرخ من حالة تشبع شرائي، ومع ذلك يظل الزخم إيجابيًا بشكل عنيد.
LINK/USDT — مخطط يومي بالشموع، مع EMA20/EMA50 والحجم.
النتائج الرئيسية
تتداول LINK عند 9.80 دولارات، محصورة عند الحد العلوي لبولينجر اليومي عند 9.81
مؤشر RSI14 اليومي عند 74.29 يضع الأصل بثبات في منطقة تشبع شرائي

سهم موديرنا (MRNA) يدخل مرحلة محورية. يظل الرسم البياني اليومي صعوديًا بقوة، بينما تُظهر الأطر الزمنية داخل اليوم تراجعًا مؤقتًا. في 19 أغسطس، أدت نتائج المرحلة الثالثة الإيجابية INTerpath-001 من موديرنا وشركة ميرك إلى إشعال عناوين بارتفاع بنسبة 50%، وهو تحرك يتجاوز بكثير آخر لقطة فنية.
MRNA — الرسم البياني اليومي مع الشموع، EMA20/EMA50 والحجم (volume).
النتائج الرئيسية
يظل الرسم البياني اليومي صعوديًا، مع إغلاق 18 أغسطس عند 62.96 فوق EMA20 وEMA50 وEMA200.
يقع مؤشر RSI14 اليومي عند 55.04، ما يترك مجالًا قبل ظروف التشبع الشرائي.

أغلقت شركة آبل (AAPL) يوم الثلاثاء عند 310.03 دولارات بعد أن سجلت نطاقًا بين 305.74 و311.49 دولارات، على 46.6 مليون سهم. تم تقسيم الإعداد: زخم التداول اليومي يتعطل بينما يبدأ الرسم البياني لكل ساعة في البناء. يعكس هذا التباين التوتر الذي يلاحظه المتداولون عند الموازنة بين المؤشرات الفنية قصيرة الأجل وتغير معنويات السوق المتعلقة بمراكزها في قطاع الذكاء الاصطناعي.
AAPL — مخطط يومي مع شموع ورسوم EMA20/EMA50 وحجم التداول.
النتائج الرئيسية
أغلقت AAPL عند 310.03 دولارات، محصورة بين متوسط 20 يومًا المتحرك (311.97 دولارًا) ومتوسط 50 يومًا (309.00 دولارات).
يتسع مدرج مؤشر MACD اليومي عند -1.66، ما يشير إلى زخم هابط على إطار التداول اليومي.

يبحث المتداولون عن المراهنة على أسهم وول ستريت بشكل متزايد عن الأسهم في البورصة نهائيًا ويتجهون مباشرةً إلى منصة بينانس. وتُظهر بيانات مشتقات جديدة أن عقود بينانس الدائمة للتقليدي-المالي (TradFi) — وهي عقود اصطناعية تتعقب كل شيء بدءًا من أسهم شركات أشباه الموصلات وحتى الفضة — أصبحت بهدوء من أكثر المنتجات ازدحامًا في البورصة، متفوقةً حتى على عدة من عقودها الدائمة المعروفة في سوق العملات المشفرة من حيث الحجم اليومي.
أبرز النقاط
باتت 10 من أصل أفضل 15 عقدًا دائمًا على بينانس من حيث حجم تداول آخر 24 ساعة عقودًا دائمة للتقليدي-المالي (TradFi) مرتبطة بالأسهم أو الصناديق المتداولة في البورصة (ETFs) أو السلع.

استعادت عملة البيتكوين هذا الأسبوع مستوى 64,000 دولار، وأشعلت هذه الحركة السعريّة الواحدة واحدةً من أقدم النقاشات في عالم العملات المشفّرة: هل حان أخيرًا الوقت لشراء العملات البديلة (altcoins) الآن، قبل أن تترك المرحلة التالية من الدورة المتأخرين خلفها؟ يجادل محلّل ومتداول في مجال العملات المشفّرة بأن الإجابة هي نعم، مستندًا إلى مزيج من الأنماط التاريخية والإشارات الفنية ومكانة إيثريوم بوصفها دليلًا على أن «ألتموسمنج» المنتظر منذ فترة طويلة قريب. أما ما إذا كان السوق الأوسع يتفق مع ذلك فمسألة أخرى تمامًا.
النتائج الرئيسية

قلبت شركة Cypherpunk Technologies الطاولة على استراتيجية Zcash الخاصة بها. بدلًا من مجرد تجميع ZEC، فعّلت الشركة—وهي شركة الخصوصية المدرجة في ناسداك—ما تصفه بأنه أكبر عملية تعدين Zcash Cypherpunk في العالم. هذه الخطوة حوّلت الشركة من مجرد مالكٍ سلبي إلى منتجٍ نشط لعملة الخصوصية التي راهنت عليها خزينتها.
أبرز النقاط
أطلقت Cypherpunk Technologies أكبر أسطول لتعدين Zcash في العالم عبر صفقة مبنية على الأسهم بقيمة 33.33 مليون دولار مع Winklevoss Capital.

استطلاع جالوب الذي يرصد حجم معارضة مراكز بيانات الذكاء الاصطناعي عبر الولايات المتحدة بأكملها، هبط كأنه «طلقة تحذير» داخل الحزب الجمهوري. وقد خلصت الدراسة إلى أن 70% من الأمريكيين يعارضون إنشاء مراكز بيانات الذكاء الاصطناعي في منطقتهم الخاصة، وتتضمن تلك النسبة تفصيلاً ينبغي أن يقلق استراتيجيي الحزب الجمهوري أكثر من أي نقطة يرددها الديمقراطيون: إذ يقول 39% من الجمهوريين إنهم يعارضون ذلك بشدة. وهذا ليس مجرد شكوى هامشية من قلة من الناشطين. بل هي تمرد على مستوى القاعدة الشعبية ضد صناعة دأب الحزب لسنوات على الترويج لها بوصفها رمزاً للهيمنة التكنولوجية الأمريكية.

يقف سهم AAPL عند مفترق طرق. أغلقت شركة آبل الجلسة الأخيرة عند 310.03 دولار، دون تغيير مقابل نقطة الارتكاز السابقة، ضمن نطاق 305.74–311.49 دولار. لقد تهدأ المخطط اليومي، بينما يبني المخطط كل ساعة حالة لارتداد قصير الأجل.
AAPL — مخطط يومي مع شموع، EMA20/EMA50 وحجم التداول.
أبرز النقاط
أغلقت شركة آبل عند 310.03 دولار، دون تغيير مقابل نقطة الارتكاز السابقة، داخل نطاق 305.74–311.49 دولار.
يظهر مؤشر القوة النسبية اليومي عند 47.86، بينما يبلغ تذبذب/مخطط الـMACD -1.66، ما يشير إلى تراجع الزخم.
يبلغ مؤشر القوة النسبية لكل ساعة 64.45 مع تذبذب/مخطط إيجابي للـMACD عند 0.52، ما يعكس اهتمامًا بالشراء على المدى القصير.

مخزون SanDisk يقع في نقطة حساسة. لا يزال الرسم البياني اليومي يُظهر اتجاهًا صاعدًا أوسع، لكن الجلسة الأخيرة أغلقت بشكل ضعيف وتُظهر إشارات التداول داخل اليوم حالة من التعب. هذا التباين بين البنية اليومية والشريط قصير الأجل يحدد الإعداد الحالي.
SAN — الرسم البياني اليومي مع الشموع، EMA20/EMA50 والحجم.
الرسائل الرئيسية
أغلق سهم SanDisk عند 14.24، أقل من المتوسط المتحرك EMA20 عند 14.34 لكنه أعلى من المتوسط المتحرك EMA50 عند 13.79 ومن المتوسط المتحرك EMA200 عند 12.24.
يقع مؤشر القوة النسبية اليومية RSI14 عند 50.83 مع مدرج تذبذب MACD بقيمة -0.03، ما يشير إلى تباطؤ الزخم بدلًا من حدوث انعكاس.

ملء خزان الوقود في ألمانيا أصبح أكثر تكلفة بشكل ملحوظ. ووفقًا لأرقام حديثة من نادي السيارات ADAC، ارتفعت أسعار الوقود في ألمانيا بشكل حاد خلال الأسبوع الماضي، حيث سجل كل من Super E10 والديزل من بين أكبر الزيادات الأسبوعية في الأشهر الأخيرة.
أهم النقاط
باتت أسعار Super E10 الآن في المتوسط 2.162 يورو لكل لتر على مستوى البلاد، بزيادة قدرها 3.7 سنتات يورو عن الأسبوع السابق.
تكلفة الديزل تبلغ في المتوسط 2.253 يورو لكل لتر، مرتفعة بمقدار 5.3 سنتات أسبوعيًا مقارنة بالأسبوع السابق.
تتداول خام برنت قرب 91 دولارًا للبرميل، أي أعلى بنحو دولارين مقارنة بالأسبوع الماضي.

Wispr، الشركة الناشئة التي تقف وراء تطبيق الإملاء بالذكاء الاصطناعي الشهير Wispr Flow، أغلقت جولة تمويل Series B بقيمة 280 مليون دولار بتقييم يبلغ 2 مليار دولار، لتكون بذلك واحدة من أكبر الرهانات حتى الآن على الحوسبة المدفوعة بالصوت. ووفقًا لمجلة Fortune، قاد Menlo Ventures جولة تمويل إملاء Wispr AI، ما يدفع إجمالي رأس المال الذي جمعته الشركة حتى الآن إلى 361 مليون دولار. إنها قفزة لافتة لشركة ناشئة جمعت جولتها السابقة قبل أقل من عام، وتشير إلى أن المستثمرين يرون واجهات الصوت أكثر بكثير من مجرد اختصار في الكتابة.

نجحت شركة Etched في تحقيق واحد من أسرع قفزات التقييم في سباق عتاد الذكاء الاصطناعي هذا العام. الشركة، التي تبني أنظمة حوسبة متخصصة لتنفيذ استدلالات الذكاء الاصطناعي، أغلقت جولة تمويل بقيمة 700 مليون دولار تقيّم الشركة عند 21 مليار دولار—وهو رقم يلفت الانتباه أكثر بحقيقة أن شركة Jane Street، وهي المستثمر الرئيسي في الجولة، تُعد أيضًا أحدث عميل مدفوع لدى Etched. تُعد جولة تمويل Etched البالغة 700 مليون دولار ثاني قفزة كبرى في التقييم للشركة خلال أقل من شهر، وتأتي مع قصة نشر واقعية على أرض الواقع، لا مجرد حماس المستثمرين.

توقع جديد لتقييم SpaceX من Meta AI يرسم مسارًا يرتفع من 205 دولارات في 2027 إلى ما يصل إلى 410 دولارات بحلول 2031 في قراءته الأكثر تفاؤلًا. ومع ذلك، يحذّر النموذج نفسه أيضًا من أن سلسلة من إخفاقات Starship أو تأخيرات تنظيمية قد تدفع التقييم إلى الهبوط نحو 95 إلى 110 دولارات بدلًا من ذلك، ما يوضح مدى اتساع نطاق النتائج المحتملة بالفعل.
أهم النقاط الرئيسية
سيناريو Meta AI الأفضل يرى أن تقييم SpaceX سيرتفع من 205 دولارات في 2027 إلى 410 دولارات بحلول 2031.
أغلقت Starlink الربع الأول مع 10.3 ملايين مشترك، وارتفعت الإيرادات بنسبة 91.9% على أساس سنوي.